The neurodegeneration in Alzheimer disease and the prion protein

Prion

Volumn 7, Issue 1, 2013, Pages 60-65

  Forloni, Gianluigi ^a   Sclip, Alessandra ^a   Borsello, Tiziana ^a   Balducci, Claudia ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Alzheimer; Neurodegeneration; Oligomers; Prion; Therapy

Indexed keywords

AMPA RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PRION PROTEIN; PRION PROTEIN ANTIBODY;

ALZHEIMER DISEASE; BINDING AFFINITY; COGNITIVE DEFECT; CONFERENCE PAPER; DESENSITIZATION; HUMAN; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PROTEIN INTERACTION; SURFACE PLASMON RESONANCE;

ALZHEIMER; NEURODEGENERATION; OLIGOMERS; PRION; THERAPY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; HUMANS; PRIONS;

EID: 84874626947     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.23286     Document Type: Conference Paper

References (85)

1. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006; 313:1781-4; PMID:16990547; http://dx.doi.org/10. 1126/science.1131864.
2. Eisele YS, Obermüller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 2010; 330:980-2; PMID:20966215; http://dx.doi.org/10.1126/science.1194516.
3. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 2010; 11:301-7; PMID:20308987; http://dx.doi.org/10.1038/nrm2873.
4. Kanouchi T, Ohkubo T, Yokota T. Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation? J Neurol Neurosurg Psychiatry 2012; 83:739-45; PMID:22544947; http://dx.doi.org/ 10.1136/jnnp-2011-301826.
5. Aguzzi A, Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 2009; 64:783-90; PMID:20064386; http://dx.doi.org/10.1016/j.neuron.2009.12.016.
6. Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science 2012; 336:1511- 3; PMID:22723400; http://dx.doi.org/10.1126/science.1222951.
7. Soto C. Transmissible proteins: expanding the prion heresy. Cell 2012; 149:968-77; PMID:22632966; http://dx.doi.org/10.1016/j.cell.2012.05.007.
8. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009; 457:1128-32; PMID:19242475; http://dx.doi.org/10.1038/nature07761.
9. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256:184-5; PMID:1566067; http://dx.doi.org/10.1126/ science.1566067.
10. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009; 110:1129-34; PMID:19457065; http://dx.doi.org/10. 1111/j.1471-4159.2009.06181.x.
11. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003; 43:545-84; PMID:12415125; http://dx.doi.org/10.1146/annurev.pharmtox.43.100901.140248.
12. Callaway E. Alzheimer's drugs take a new tack. Nature 2012; 489:13-4; PMID:22962697; http://dx.doi.org/10.1038/489013a.
13. Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur J Pharmacol 1991; 207:367-8; PMID:1783006; http://dx.doi.org/10.1016/0922-4106(91) 90014-9.
14. Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol 1997; 4:119-25; PMID:9190286; http://dx.doi.org/10.1016/S1074-5521(97)90255-6.
15. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 1997; 272:22364-72; PMID:9268388; http://dx.doi.org/10.1074/jbc.272.35. 22364.
16. Forloni G, Lucca E, Angeretti N, Della Torre P, Salmona M. Amidation of beta-amyloid peptide strongly reduced the amyloidogenic activity without alteration of the neurotoxicity. J Neurochem 1997; 69:2048-54; PMID:9349550; http://dx.doi.org/10.1046/j.1471-4159.1997.69052048.x.
17. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998; 95:6448-53; PMID:9600986; http://dx.doi.org/10.1073/pnas.95.11.6448.
18. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416:535-9 PMID:11932745; http://dx.doi.org/10.1038/416535a.
19. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, et al. Synaptic targeting by Alzheimer'srelated amyloid beta oligomers. J Neurosci 2004; 24:10191-200; PMID:15537891; http://dx.doi.org/10.1523/JNEUROSCI.3432-04. 2004.
20. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 2003; 100:10417- 22; PMID:12925731; http://dx.doi.org/10.1073/pnas. 1834302100.
21. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, et al. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 2005; 95:834-47; PMID:16135089; http://dx.doi.org/10.1111/j.1471-4159.2005.03407.x.
22. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001; 4:887-93; PMID:11528419; http://dx.doi.org/10.1038/nn0901-887.
23. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, et al. A new amyloid beta variant favoring oligomerization in Alzheimer'stype dementia. Ann Neurol 2008; 63:377-87; PMID:18300294; http://dx.doi.org/10.1002/ ana.21321.
24. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A 1999; 96:3228-33; PMID:10077666; http://dx.doi.org/10.1073/pnas.96.6.3228.
25. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin- 1 mutations: lack of association with amyloid deposits. Behav Genet 1999; 29:177-85; PMID:10547924; http://dx.doi.org/10.1023/A:1021691918517.
26. Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 2003; 17:388-96; PMID:12542676; http://dx.doi.org/10. 1046/j.1460-9568.2003.02444.x.
27. Balducci C, Tonini R, Zianni E, Nazzaro C, Fiordaliso F, Salio M, et al. Cognitive deficits associated with alteration of synaptic metaplasticity precede plaque deposition in AßPP23 transgenic mice. J. Alzh Dis. 2010; 21:1367-81.
28. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990; 27:457- 64; PMID:2360787; http://dx.doi.org/10.1002/ana.410270502.
29. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, et al. Prion-like behaviour and taudependent cytotoxicity of pyroglutamylated amyloid-β. Nature 2012; 485:651-5; PMID:22660329; http://dx.doi.org/10. 1038/nature11060.
30. Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012; 15:349-57; PMID:22286176; http://dx.doi.org/10.1038/nn.3028.
31. Lee J, Culyba EK, Powers ET, Kelly JW. Amyloid-β forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol 2011; 7:602-9; PMID:21804535; http://dx.doi.org/10.1038/nchembio.624.
32. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440:352- 7; PMID:16541076; http://dx.doi.org/10.1038/nature04533.
33. Reed MN, Hofmeister JJ, Jungbauer L, Welzel AT, Yu C, Sherman MA, et al. Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol Aging 2011; 32:1784-94; PMID:20031278; http://dx.doi.org/10.1016/j. neurobiolaging.2009.11.007.
34. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, et al. Self-assembly of Abeta(1- 42) into globular neurotoxins. Biochemistry 2003; 42:12749-60; PMID:14596589; http://dx.doi.org/10.1021/bi030029q.
35. Ladiwala AR, Litt J, Kane RS, Aucoin DS, Smith SO, Ranjan S, et al. Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity. J Biol Chem 2012; 287:24765-73; PMID:22547072; http://dx.doi.org/10.1074/jbc.M111.329763.
36. Zampagni M, Cascella R, Casamenti F, Grossi C, Evangelisti E, Wright D, et al. A comparison of the biochemical modifications caused by toxic and non-toxic protein oligomers in cells. J Cell Mol Med 2011; 15:2106-16; PMID:21155974; http://dx.doi.org/10.1111/j.1582-4934.2010.01239.x.
37. Stravalaci M, Bastone A, Beeg M, Cagnotto A, Colombo L, Di Fede G, et al. Specific recognition of biologically active amyloid-β oligomers by a new surface plasmon resonance-based immunoassay and an in vivo assay in Caenorhabditis elegans. J Biol Chem 2012; 287:27796-805; PMID:22736768; http://dx.doi.org/10.1074/jbc.M111.334979.
38. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005; 8:79-84; PMID:15608634; http://dx.doi.org/10.1038/nn1372.
39. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14:837-42; PMID:18568035; http://dx.doi.org/10.1038/nm1782.
40. Scopes DI, O'Hare E, Jeggo R, Whyment AD, Spanswick D, Kim EM, et al. Aβ oligomer toxicity inhibitor protects memory in models of synaptic toxicity. Br J Pharmacol 2012; 167:383-92; PMID:22913627; http://dx.doi.org/10. 1111/j.1476-5381.2012.01973.x.
41. Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A 2010; 107:2295-300; PMID:20133875; http://dx.doi.org/10.1073/pnas.0911829107.
42. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009; 62:788-801; PMID:19555648; http://dx.doi.org/10.1016/j.neuron.2009.05.012.
43. Mucke L, Selkoe DJ. Neurotoxicity of Amyloid β-Protein: Synaptic and Network Dysfunction. Cold Spring Harb Perspect Med 2012; 2:a006338; PMID:22762015.
44. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005; 8:1051-8; PMID:16025111; http://dx.doi.org/10.1038/nn1503.
45. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007; 27:2866-75; PMID:17360908; http://dx.doi.org/10.1523/ JNEUROSCI.4970-06.2007.
46. Ferreira IL, Bajouco LM, Mota SI, Auberson YP, Oliveira CR, Rego AC. Amyloid beta peptide 1-42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-daspartate receptors in cortical cultures. Cell Calcium 2012; 51:95-106; PMID:22177709; http://dx.doi.org/10. 1016/j.ceca.2011.11.008.
47. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble Aβ oligomers inhibit longterm potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 2011; 31:6627- 38; PMID:21543591; http://dx.doi.org/10.1523/ JNEUROSCI.0203-11.2011.
48. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 2004; 24:3370-8; PMID:15056716; http://dx.doi.org/10.1523/JNEUROSCI.1633-03.2004.
49. Tackenberg C, Brandt R. Divergent pathways mediate spine alterations and cell death induced by amyloidbeta, wild-type tau, and R406W tau. J Neurosci 2009; 29:14439-50; PMID:19923278; http://dx.doi.org/10.1523/JNEUROSCI.3590-09. 2009.
50. Sclip A, Antoniou X, Colombo A, Camici GG, Pozzi L, Cardinetti D, et al. c-Jun N-terminal kinase regulates soluble Aβ oligomers and cognitive impairment in AD mouse model. J Biol Chem 2011; 286:43871- 80; PMID:22033930; http://dx.doi.org/10.1074/jbc. M111.297515.
51. Mota SI, Ferreira IL, Pereira C, Oliveira CR, Rego AC. Amyloid-beta peptide 1-42 causes microtubule deregulation through N-methyl-D-aspartate receptors in mature hippocampal cultures. [Epub ahead of print]. Curr Alzheimer Res 2012; 9:844-56; PMID:22631440; http://dx.doi.org/10.2174/156720512802455322.
52. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 2009; 106:1971- 6; PMID:19188609; http://dx.doi.org/10.1073/pnas.0809158106.
53. Bomfim TR, Forny-Germano L, Sathler LB, Brito- Moreira J, Houzel JC, Decker H, et al. An antidiabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. J Clin Invest 2012; 122:1339- 53; PMID:22476196; http://dx.doi.org/10.1172/ JCI57256.
54. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382:685-91; PMID:8751438; http://dx.doi.org/10.1038/382685a0.
55. Kook SY, Hong HS, Moon M, Ha CM, Chang S, Mook-Jung IA. Aβ1-42-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca2+- calcineurin signaling. J Neurosci 2012; 32:8845- 54; PMID:22745485; http://dx.doi.org/10.1523/JNEUROSCI.6102-11.2012.
56. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007; 27:796- 807; PMID:17251419; http://dx.doi.org/10.1523/JNEUROSCI. 3501-06.2007.
57. Cissé M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 2011; 469:47-52; PMID:21113149; http://dx.doi.org/10.1038/nature09635.
58. Fu W, Ruangkittisakul A, MacTavish D, Shi JY, Ballanyi K, Jhamandas JH. Amyloid β (Aβ) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways. J Biol Chem 2012; 287:18820-30; PMID:22500019; http://dx.doi.org/10.1074/jbc.M111.331181.
59. De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging 2008; 29:1334-47; PMID:17403556; http://dx.doi.org/10.1016/j.neurobiolaging.2007.02.029.
60. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 2011; 108:5819-24; PMID:21421841; http://dx.doi.org/10.1073/pnas.1017033108.
61. Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 2009; 29:9078-89; PMID:19605645; http://dx.doi.org/10.1523/JNEUROSCI.1071-09.2009.
62. Chen S, Yadav SP, Surewicz WK. Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues. J Biol Chem 2010; 285:26377-83; PMID:20576610; http://dx.doi.org/10.1074/jbc.M110.145516.
63. Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, et al. Prion protein and Abetarelated synaptic toxicity impairment. EMBO Mol Med 2010; 2:306-14; PMID:20665634; http://dx.doi.org/10.1002/emmm.201000082.
64. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Laurén J, Gimbel ZA, et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci 2010; 30:6367-74; PMID:20445063; http://dx.doi.org/10.1523/ JNEUROSCI.0395-10.2010.
65. Chung E, Ji Y, Sun Y, Kascsak RJ, Kascsak RB, Mehta PD, et al. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci 2010; 11:130; PMID:20946660; http://dx.doi.org/10.1186/1471-2202-11-130.
66. Kessels HW, Nguyen LN, Nabavi S, Malinow R. The prion protein as a receptor for amyloid-beta. Nature 2010; 466:E3-4, discussion E4-5; PMID:20703260; http://dx.doi.org/10.1038/nature09217.
67. Barry AE, Klyubin I, Mc Donald JM, Mably AJ, Farrell MA, Scott M, et al. Alzheimer's disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J Neurosci 2011; 31:7259-63; PMID:21593310; http://dx.doi.org/10.1523/JNEUROSCI.6500-10.2011.
68. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, et al. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 2012; 15:1227-35; PMID:22820466; http://dx.doi.org/10.1038/nn.3178.
69. You H, Tsutsui S, Hameed S, Kannanayakal TJ, Chen L, Xia P, et al. Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A 2012; 109:1737-42; PMID:22307640; http://dx.doi.org/10.1073/pnas.1110789109.
70. Freir DB, Nicoll AJ, Klyubin I, Panico S, Mc Donald JM, Risse E, et al. Interaction between prion protein and toxic Aß assemblies can be therapeutically targeted at multiple sites. Nature Commun 2011; 2:336; http://dx.doi.org/10.1038/ncomms1341.
71. Bate C, Williams A. Amyloid-β-induced synapse damage is mediated via cross-linkage of cellular prion proteins. J Biol Chem 2011; 286:37955-63; PMID:21900234; http://dx.doi.org/10.1074/jbc.M111.248724.
72. Cissé M, Sanchez PE, Kim DH, Ho K, Yu GQ, Mucke L. Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J Neurosci 2011; 31:10427-31; PMID:21775587; http://dx.doi.org/10.1523/JNEUROSCI.1459-11.2011.
73. Virok DP, Simon D, Bozsó Z, Rajkó R, Datki Z, Bálint É, et al. Protein array based interactome analysis of amyloid-β indicates an inhibition of protein translation. J Proteome Res 2011; 10:1538-47; PMID:21244100; http://dx.doi.org/10.1021/pr1009096.
74. Manzoni C, Colombo L, Bigini P, Diana V, Cagnotto A, Messa M, et al. The molecular assembly of amyloid aβ controls its neurotoxicity and binding to cellular proteins. PLoS One 2011; 6:e24909; PMID:21966382; http://dx.doi.org/10. 1371/journal.pone.0024909.
75. Forloni G, Balducci C. β-amyloid oligomers and prion protein: Fatal attraction? Prion 2011; 5:10- 5; PMID:21150333; http://dx.doi.org/10.4161/pri.5. 1.14367.
76. Westaway D, Jhamandas JH. The P's and Q's of cellular PrP-Aβ interactions. Prion 2012; 6:359- 63; PMID:22874673; http://dx.doi.org/10.4161/ pri.20675.
77. Zanata SM, Lopes MH, Mercadante AF, Hajj GN, Chiarini LB, Nomizo R, et al. Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection. EMBO J 2002; 21:3307-16; PMID:12093732; http://dx.doi.org/10.1093/emboj/cdf325.
78. Martins VR, Beraldo FH, Hajj GN, Lopes MH, Lee KS, Prado MM, et al. Prion protein: orchestrating neurotrophic activities. Curr Issues Mol Biol 2010; 12:63-86; PMID:19767651.
79. Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR. Physiology of the prion protein. Physiol Rev 2008; 88:673-728; PMID:18391177; http://dx.doi.org/10.1152/physrev.00007.2007.
80. Turnbaugh JA, Westergard L, Unterberger U, Biasini E, Harris DA. The N-terminal, polybasic region is critical for prion protein neuroprotective activity. PLoS One 2011; 6:e25675; PMID:21980526; http://dx.doi.org/10.1371/ journal.pone.0025675.
81. Rial D, Piermartiri TC, Duarte FS, Tasca CI, Walz R, Prediger RD. Overexpression of cellular prion protein (PrP(C)) prevents cognitive dysfunction and apoptotic neuronal cell death induced by amyloid-β (Aβ1-40) administration in mice. Neuroscience 2012; 215:79- 89; PMID:22537845; http://dx.doi.org/10.1016/j.neuroscience.2012.04.034.
82. Nieznanski K, Choi JK, Chen S, Surewicz K, Surewicz WK. Soluble prion protein inhibits amyloid-β (Aβ) fibrillization and toxicity. J Biol Chem 2012; 287:33104-8; PMID:22915585; http://dx.doi.org/10.1074/jbc.C112. 400614.
83. Vincent B, Paitel E, Saftig P, Frobert Y, Hartmann D, De Strooper B, et al. The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol esterregulated normal cleavage of the cellular prion protein. J Biol Chem 2001; 276:37743-6; PMID:11477090.
84. Guillot-Sestier MV, Sunyach C, Druon C, Scarzello S, Checler F. The α-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo. J Biol Chem 2009; 284:35973- 86; PMID:19850936; http://dx.doi.org/10.1074/jbc.M109.051086.
85. Guillot-Sestier MV, Sunyach C, Ferreira ST, Marzolo MP, Bauer C, Thevenet A, et al. α-Secretase-derived fragment of cellular prion, N1, protects against monomeric and oligomeric amyloid β (Aβ)- associated cell death. J Biol Chem 2012; 287:5021- 32; PMID:22184125; http://dx.doi.org/10.1074/ jbc.M111.323626.